BLACKLEDGER Investing Watch: ANET, UEC, VKTX
BLACKLEDGER's latest investing watch update tracks ANET, UEC, VKTX, TSLA, RGTI, RXRX from the active public watchlist. This post is built from public-safe status data, in-house public signal labels, and outside public source context. It is designed to help readers understand what is happening around each asset without exposing private research methods.
Investing Watch Data
The dedicated feed category for this update is Investing. The latest public scan timestamp is 2026-07-07T08:00:54.247390+00:00.
- ANET (stock): Bull public bias, Extended, public score 9.0/10, status: Paper trading research.
- UEC (stock): Bear public bias, Extended, public score 9.0/10, status: Paper trading research.
- VKTX (stock): Bull public bias, Extended, public score 9.0/10, status: Paper trading research.
- TSLA (stock): Bull public bias, Extended, public score 9.0/10, status: Paper trading research.
- RGTI (stock): Bear public bias, Extended, public score 9.0/10, status: Paper trading research.
- RXRX (stock): Bull public bias, Extended, public score 8.3/10, status: Paper trading research.
- BBAI (stock): Bear public bias, Extended, public score 8.3/10, status: Paper trading research.
- RIVN (stock): Bull public bias, Extended, public score 8.0/10, status: Paper trading research.
Educational Context: How To Use This Page
This page is not a trade instruction. It is an educational research brief. Readers can use it to understand company or project background, public market context, public status labels, and relevant outside-source headlines before doing their own due diligence.
ANET Public Research Bio
Name: Arista Networks, Inc.. Market class: stock. Public bias: Bull. Public tier: Extended.
Arista Networks, Inc. engages in the development, marketing, and sale of data-driven, client to cloud networking solutions for AI, data center, campus, and routing environments in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. Its cloud networking solutions consist of Extensible Operating System (EOS), a publish-subscribe state-sharing networking operating system offered in combination with a set of network applications. The company offers data center, cloud and AI networking, cognitive adjacencies, and cognitive network software and services. It also provides post contract customer support services, such as technical support, hardware repair and replacement parts beyond standard warranty, bug fixes, patches, and upgrade services. The company serves a range of industries comprising internet companies, cloud service providers, financial services organizations, government agencies, media and entertainment, healthcare
- Latest public price/reference: $173.2
- Public market capitalization: $218.19B
- Recent public volume/reference: 8.50M
- One-month public movement: 2.41%
- Sector/category: Technology
Why ANET Is In This Public Update
- BLACKLEDGER public score is in the upgrade-candidate band, so the asset receives expanded public context.
- Current public status: Paper trading research. Public confidence label: High Confidence.
- Current public directional label: bull. This is research context only, not an execution instruction.
Outside Public Headlines / Source Notes
- The Wide-Open Possibilities The Options Market Sees In Cisco Stock — Trefis
- Can Cisco's AI Networking Momentum Lift CSCO Stock Higher? — Zacks
- What Makes Arista Networks (ANET) One of BlackRock’s 30 Most Important AI Stocks — Insider Monkey
- Here’s How Arista Networks Is a Major Beneficiary of Big Tech’s Push to Break Nvidia’s Grip — Barchart
UEC Public Research Bio
Name: Uranium Energy Corp.. Market class: stock. Public bias: Bear. Public tier: Extended.
Uranium Energy Corp., together with its subsidiaries, engages in exploration, pre-extraction, extraction, and processing of uranium and titanium concentrates properties in the United States, Canada, and the Republic of Paraguay. The company was formerly known as Carlin Gold Inc. and changed its name to Uranium Energy Corp. in January 2005. The company was incorporated in 2003 and is headquartered in Corpus Christi, Texas.
- Latest public price/reference: $10.57
- Public market capitalization: $5.24B
- Recent public volume/reference: 6.44M
- One-month public movement: -8.29%
- Sector/category: Energy
Why UEC Is In This Public Update
- BLACKLEDGER public score is in the upgrade-candidate band, so the asset receives expanded public context.
- Current public status: Paper trading research. Public confidence label: High Confidence.
- Current public directional label: bear. This is research context only, not an execution instruction.
Outside Public Headlines / Source Notes
- CCJ Trades at a Premium Valuation: Buy, Sell or Hold the Stock? — Zacks
- Brokers Suggest Investing in Uranium Energy (UEC): Read This Before Placing a Bet — Zacks
- Cameco vs. Centrus Energy: Which Uranium Stock is the Better Buy Now? — Zacks
- Optimism Surrounds Uranium Energy (UEC) Following an Impressive Quarter — Insider Monkey
VKTX Public Research Bio
Name: Viking Therapeutics, Inc.. Market class: stock. Public bias: Bull. Public tier: Extended.
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystr
- Latest public price/reference: $38.73
- Public market capitalization: $4.49B
- Recent public volume/reference: 2.12M
- One-month public movement: 20.69%
- Sector/category: Healthcare
Why VKTX Is In This Public Update
- BLACKLEDGER public score is in the upgrade-candidate band, so the asset receives expanded public context.
- Current public status: Paper trading research. Public confidence label: High Confidence.
- Current public directional label: bull. This is research context only, not an execution instruction.
Outside Public Headlines / Source Notes
- CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? — Motley Fool
- Could This Healthcare Stock Help You Build a Real Fortune Over the Next 20 Years? — Motley Fool
- How Much Could $1,000 Invested in Viking Therapeutics Be Worth by 2030? — Motley Fool
- Is Viking Therapeutics Stock Going to $50? Here's What the Bulls and Bears Are Saying — Motley Fool
TSLA Public Research Bio
Name: Tesla, Inc.. Market class: stock. Public bias: Bull. Public tier: Extended.
Tesla, Inc. designs, develops, manufactures, leases, and sells electric vehicles, and energy generation and storage systems in the United States, China, and internationally. The company operates in two segments, Automotive; and Energy Generation and Storage. The company offers electric vehicles, as well as sells automotive regulatory credits; and non-warranty maintenance services and collision, automotive insurance services, as well as part sales and retail merchandise sale. It also provides sedans and sport utility vehicles through direct and used vehicle sales, a network of Tesla Superchargers, and in-app upgrades; purchase financing and leasing services; services for electric vehicles through its company-owned service locations and Tesla mobile service technicians; and vehicle limited warranties and extended service plans. In addition, the company engages in the design, manufacture, installation, sale, and leasing of solar energy gen
- Latest public price/reference: $419.8
- Public market capitalization: $1576.54B
- Recent public volume/reference: 51.65M
- One-month public movement: 2.43%
- Sector/category: Consumer Cyclical
Why TSLA Is In This Public Update
- BLACKLEDGER public score is in the upgrade-candidate band, so the asset receives expanded public context.
- Current public status: Paper trading research. Public confidence label: High Confidence.
- Current public directional label: bull. This is research context only, not an execution instruction.
Outside Public Headlines / Source Notes
- Stock market today: Dow posts record, S&P 500 and Nasdaq rally on revived AI optimism — Yahoo Finance
- Tesla (TSLA) Launches Miami Robotaxi Service, Is The Upside Already Priced In? — Simply Wall St.
- Tesla's Robotaxi Just Launched in Miami -- Its First City Outside Texas and California. Can It Rescue the Stock? — Motley Fool
- Waymo outages disrupt traffic in this major city yet again — TheStreet
RGTI Public Research Bio
Name: Rigetti Computing, Inc.. Market class: stock. Public bias: Bear. Public tier: Extended.
Rigetti Computing, Inc., through its subsidiaries, builds and operates quantum computers and the superconducting quantum processors the United States, the United Kingdom, rest of Europe, Asia, and internationally. The company offers quantum processing units (QPUs) and quantum computing systems to provide access to quantum computing systems through the cloud in the form of quantum computing as a service (QCaaS). It provides Novera, a 9-qubit chip QPU that features tunable couplers for fast two-qubit operations and a 5-qubit chip for testing single-qubit operations; Novera QPU that is based in fourth generation Ankaa-class architecture; 36-qubit Cepheus-1-36Q system, a multi-chip quantum computer; and 84-qubit Ankaa-3 quantum computer. The company also sells access to its quantum computers through QCaaS. In addition, the company offers Rigetti quantum cloud services, a platform that provides support for various range of programming capabi
- Latest public price/reference: $17.96
- Public market capitalization: $5.97B
- Recent public volume/reference: 19.00M
- One-month public movement: -15.22%
- Sector/category: Technology
Why RGTI Is In This Public Update
- BLACKLEDGER public score is in the upgrade-candidate band, so the asset receives expanded public context.
- Current public status: Paper trading research. Public confidence label: High Confidence.
- Current public directional label: bear. This is research context only, not an execution instruction.
Outside Public Headlines / Source Notes
- Rigetti Expands Quantum Reach Beyond the Race for More Qubits — Zacks
- 3 Quantum Computing Stocks to Buy in July — 24/7 Wall St.
- Rigetti Computing, Inc. (RGTI) Stock Moves -3.85%: What You Should Know — Zacks
- A Revolutionary Technology Narrative Has Surged—Don’t Take the Bait — 24/7 Wall St.
RXRX Public Research Bio
Deep bio flag: This asset reached the 9+ public rating threshold, so BLACKLEDGER includes a fuller company/project profile, outside-source context, and public education notes.
Name: Recu[redacted]on Pharmaceuticals, Inc.. Market class: stock. Public bias: Bull. Public tier: Extended.
Recu[redacted]on Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reve[redacted]ble, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and h[redacted]tology oncology. Its preclinical stage product includes REC-7735 for the treatment of
- Latest public price/reference: $3.96
- Public market capitalization: $2.10B
- Recent public volume/reference: 33.85M
- One-month public movement: 25.52%
- Sector/category: Healthcare
Why RXRX Is In This Public Update
- BLACKLEDGER public score is in the 7.0-8.9 confirmation band (the most reliable tier), so this asset receives a deep public bio and outside-source review.
- Current public status: Paper trading research. Public confidence label: High Confidence.
- Current public directional label: bull. This is research context only, not an execution instruction.
Outside Public Headlines / Source Notes
- Recu[redacted]on Pharmaceuticals (RXRX) Is Up 8.0% After Russell Index Additions Expand Its Investor Base – Has The Bull Case Changed? — Simply Wall St.
- Recu[redacted]on Pharmaceuticals (RXRX) Stock Looks Fully Valued Despite AI Drug Hopes — Simply Wall St.
- Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought — Motley Fool
- Dyne Therapeutics vs. Recu[redacted]on Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026? — Motley Fool
What The Public Data Shows
The public feed highlights ticker status, market class, directional bias, score, tier, confidence, company or project profile, public market references, and outside-source headlines. These fields support a deeper view of BLACKLEDGER's public research feed while keeping private methods undisclosed.
Why This Category Matters
The Investing section gives readers a focused path through the market: buying watch content for constructive candidates, selling watch content for defensive movement, investing content for higher-quality public watch names, and market trend notes for broader context.
Research-Only Notice
BLACKLEDGER content is market research only. There is no live execution signal, no recommendation to buy or sell, and no financial advice. Readers should perform their own due diligence and consult licensed professionals before making financial decisions.
Research-only. No execution signal. Not financial advice.